Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Sweden
Finland
Denmark
Norway
Latest
Trending
Followed

Xbrane Biopharma, Webcast, Q3'25

By Inderes10/24/2025, 7:00 AM
Xbrane Biopharma

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Martin
00:00 - 11:50

Join our webcast for the quarterly report for the third quarter of 2025. My name is Martin. I'm the CEO of Xbrane Biopharma, and I also have with me today our CFO, Jane. We usually start by going through the operational highlights of the quarter, and then Jane will go through the financial highlights, followed by some minutes for Q&A towards the end. You can ask questions either via the audio function if you've called in or via the chat. Join our webcast concerning our quarterly report for the third quarter of 2025. So we'll start with Ximluci®, our Lucentis biosimilar, with which we have partnered. Stada has currently launched in 24 countries, out of which 20 are in Europe and four in the Asia-Middle East region. It's quite a straightforward collaboration, where we are essentially sharing the profit contribution 50/50 from the sales and marketing of this product. And just to have a look at the market situation to start with, this is a biosimilar to Lucentis with the active ingredient Ranibizumab. And we have Ximluci®, a biologic, alongside three other biosimilars to Lucentis on the market. So you can see that there's a dark blue part on the bottom representing Lucentis, the originator, as well as the Lucentis biosimilars on the market. And then if we consider the broader class of drugs, retinal anti-VEGFs, we also have the originator product, Eylea, as well as Vabysmo. And then we have certain off-label usage of the cancer drug Avastin. All in all, this is a market of about €5 billion across Europe. It has been growing at around 7% per year in volume and 5.5% in value. And we're seeing quite a lot of developments in this market. It's a sizable market and it is growing. However, Vabysmo, the new product launched by Roche, is also taking market share in the overall market and in the Eylea space. We are going to see biosimilars entering the market starting from the end of this year onwards. If we look at Ximluci® and the performance of Ximluci®, we had more or less a constant volume in Q3 compared to Q2, and that is the volume that STADA sold to end customers. And market share from a volume perspective was also retained at about 8%. Then again, that is the market share within the Ranibizumab market. So, versus Lucentis and the Lucentis biosimilars, Ximluci® is the market leader among the biosimilars in Italy and Germany. Tada! Right now, I think there are good opportunities for continued growth during next year. There are a couple of exciting tenders where STADA is going to participate, so we do believe that the growth is going to resume during next year. And we also resumed the shipments of the product to STADA this quarter. And that will continue in the coming quarters, 5 or 6 quarters, as far as we have that forecast, if you will. Total profit generation accumulated so far is about 150 million Swedish crowns. And we also do have an inventory of drug substance, mainly when it comes to Ximluci® amounting to about 170 million Swedish crowns. As shipments to stores are being resumed, it is being converted into cash continuously. Then switching over to the US. As most of you probably know, we unfortunately faced a delay with regards to FDA approval. We received a so-called complete response letter to our application from the FDA. And that was quite generic in terms of the stated reasons for not being able to approve the application. It mentioned that it was due to unresolved observations at one of the manufacturing sites. What then happens is that the site, which is a contract manufacturer—we don't have our own manufacturing site, so this is a contract manufacturer. Therefore, the FDA is also conscious about maintaining confidentiality. Not revealing information to us. They are not permitted by the contract manufacturer to reveal that information to us. So the site will receive more information. Soon. They haven't received it yet. Last time, we saw some information being received. Five days post CRL. So, we do expect that information to come. Yes. These days, there will essentially be more information from the FDA. What were the specific observations from the inspection they conducted? End of August, they felt were unresolved by the responses the production site submitted. We really need that information in order to be able to finalize the timing for the resubmission of the BLA. We do believe, though, that we are looking towards a resubmission in the first quarter of next year. That is based on essentially the corrective actions, which are ongoing at the production site. Following a few of the observations from the recent inspection by the FDA, are going to be finalized in the beginning of next year. And then we believe that this will be able to trigger a resubmission. But then again, we really need this information from the FDA to be able to confirm that timeline. It is then a six-month review timeline expected from a resubmission until the date, and hopefully this time around, an approval. We understand, of course, that many of you are disappointed about this, and we are also very disappointed about this outcome. It is absolutely not what we expected or had hoped for. But we really now have to wait for information from the FDA, fully understand the issues they see, and then work together with our contract manufacturer to swiftly resolve these issues and move towards a resubmission. Let's switch gears to our next event program. Biosimilar candidate to Opdivo®. As far as we can tell, this is one out of four biosimilars to Opdivo® currently in clinic. We believe we have a timeline that will permit a launch in the US on day one, so to speak. So immediately post-patent expiration date is December 2028. We can note here that we can go to the next slide that the clinical trial is initiated by our partner Intas. We are, on our end, going through our development responsibilities of process characterization and validation, which is a key element, of course, of an application. I think if there's one big lesson to draw from our issues with regards to Ximluci® and the FDA, it is that you should really make sure to work with manufacturing sites and contract manufacturers with a long history of successful FDA inspections and long-time supply of product to the US market. We made sure to do that for this program. We're working with one of the largest contract manufacturers globally and sites with a long history of successful FDA inspections and currently supplying product to the US market. We're doing everything we can together with our partner, Intas, to carry this development through so that we can make a submission to the FDA in the fourth quarter of 2027, allowing for approval by the end of 2028. Loss of exclusivity by the originator. And this is a very sizable opportunity for us. We do believe it could generate a billion Swedish crowns annually. To explain, based on how historical oncology biosimilars have performed in the US and based on the profit split we have agreed with our partner, it is a very sizable opportunity for us. But of course, it hinges a lot upon a timely approval first in the US. So that's what we're fully focused on. But I do believe that we have a timeline and a setup now which allows for that. So I'm quite excited about this program actually. Let's switch gears to our next event program. So with that said, I'm going to hand over to Jane to go through the financials.

Jane
11:52 - 15:42

Let's switch gears to our next event program. Revenue for the quarter increased again with shipping to STADA. And the total revenue of shipped products amounted to 10.7 million Swedish crowns. The received profit sharing amounted to 9 million Swedish crowns. However, there was an adjustment made to the expected profit sharing with -10 million Swedish crowns, which made the total net revenue amount to 10 million Swedish crowns for the total quarter. And we expect to pick up more shipments during the coming quarters. And some of the shipments have been delayed in the third quarter. This is the reason that the revenue from the shipment was a little bit lower than expected. We have ongoing measures to reduce our production costs together with our partner STADA, and these will materialize in the coming years. So the expenses of the new Xbrane, so to speak, have been reduced as we had anticipated. The administration expenses amounted to 8 million Swedish crowns for the third quarter, and the research and development expenses amounted to 10 million Swedish crowns, whereof 2.8 million Swedish crowns refer to the amortization of our intangible assets. Overall, we have the fixed costs amounting to approximately 11 million Swedish crowns on a quarterly basis. We also wanted to visualize the cash position as of the end of the third quarter, and we concluded a directed share issue in July, which provided 240 million Swedish crowns. The amount of that accumulated accounts payable was 91 million Swedish crowns. We had some production costs related to the FDA inspections amounting to 4 million Swedish crowns and also the profit-sharing, as I mentioned. Amounting to a positive 9 million Swedish crowns. The fixed cost amounts to 11 million Swedish crowns and consists of salaries overall. Consultant costs include basically everything that keeps the show going, so to speak. The development costs of our current program amounted to 27 million Swedish crowns. We have some other cash flow items of a non-recurring kind, amounting to 5 million Swedish crowns, which gave us a closing cash balance of 94 million Swedish crowns. So basically, the operating cash flow amounted to 49 million Swedish crowns. And the cash at the end of the period amounted to 94 million Swedish crowns.

Martin
15:46 - 17:34

Yeah. The key takeaways from the quarter include Ximluci® currently being present in 24 countries, with a constant volume growth compared to Q2. But we do see opportunities, which we are working together with our team for growth to resume coming in next year. Delay in the FDA approval of Ximluci®, as we discussed, with potential resubmission in the first quarter of next year and a new update in Q3 next year. Xbrane's ongoing clinical trial and development are on track towards a day one launch, and as Jane described, we are now focusing on working with our contract manufacturer on Ximluci® and with the FDA to move towards a resubmission and eventually approval of Ximluci® in the US. When it comes to Ximluci®, we are also working on several production cost reduction measures together with the staff, so that over the coming years, we will be able to bring down production costs. And then, of course, our development responsibility consists of process characterization and validation; these are our priorities for the remainder of this year and next. So with that said, we can shift over to Q&A. And I guess we'll start with the potential questions from listeners calling in.

Operator
17:39 - 18:02

If you wish to ask a question, please dial Pound Key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial the Pound Key on your telephone keypad. The next question comes from Philip Ineson from Redeye. Please go ahead.

Philip Ineson
18:05 - 18:19

Hello, everyone. So I just wanted to start on volume growth, as you mentioned. There was no volume growth from Q2. Could you expand a bit on the trend in the decline?

Martin
18:21 - 19:29

Yes, it was a constant volume, Q3 versus Q2. Yes. Essentially, I think this depends on, on the one hand, competition from the general market, the originator, and the other biosimilars. We do see an increased price pressure in that market, if you will. So that's one part of it. And there's an element which involves active work, particularly by STADA, to participate in new tenders, to be able to unlock new volume, something which takes time. According to the forecast we have together with them, we are looking toward 2026 with quite significant growth compared to 2025. I would read it as a temporary decline in growth.

Philip Ineson
19:31 - 19:43

Okay, good, good. And the second topic is regarding the profits. Split. Can you again clarify what it was in Q3 and also the 10 million adjustment, just to make it a bit clearer?

Martin
19:48 - 20:29

So, this probably relates a bit to how we handle revenue recognition. So we shipped the product to STADA. For that shipment, we expect the 10 million Swedish crown profit sharing. Then there was also 10 million related to the supply price, which is according to COGS. And then, we also needed to make an adjustment for the expected profit sharing from the product already shipped to STADA. So that resulted in a -10 million. Am I describing that correctly?

Jane
20:29 - 20:30

Yes, that is correct.

Martin
20:30 - 20:31

Yeah.

Philip Ineson
20:32 - 20:46

Could you just expand a bit on this trend of decline? Good. And also just to clarify, as I understood it, there's been no news from the FDA. Has there been any new dialogue with the contract manufacturer that you could shed some light on?

Martin
20:47 - 21:15

We are maintaining a continuous dialogue with the contract manufacturer. However, they have not received any further information from the FDA. We do expect that to come in the coming days. Essentially, last time we had a five-day time period between the complete response letter and a so-called follow-up letter that is coming to the site following a complete response letter.

Philip Ineson
21:20 - 21:24

Could you just expand a bit on this trend on the decline? So next week is a good guess.

Martin
21:24 - 21:25

Yes.

Philip Ineson
21:27 - 21:36

Good. And okay, so trying to understand the cost base a little bit, would you say that Q3 is sort of a good picture of the fixed cost base moving forward?

Jane
21:38 - 22:02

I would say that it's quite representative in terms of the fixed costs. Yes, I would. However, one must also remember that we have obligations to maintain in terms of the development. Therefore, the cash outflow is not just consistent with the fixed costs, but also with the development obligations that we are currently working on.

Philip Ineson
22:06 - 22:25

So next week then is a good guess. And also one last, if I may, previously we have been talking a lot about the prefilled syringe, and it was viewed as a key element to increase market adoption. Can we get an update on the current status? And, I mean, we haven't spoken a lot about it lately.

Martin
22:27 - 23:04

Yes. We still have it in development, but we need to clarify if we need to revise the timeline somehow. It's going to depend on the remaining investments and when we, together, are willing to make them. So, we need to get back on an expected timing for the submission, approval, and launch of the prefilled syringe.

Philip Ineson
23:07 - 23:09

Okay, that was all for me. So next week then is a good guess.

Operator
23:18 - 23:43

As a reminder, if you wish to ask a question, please dial the pound key on your telephone keypad. There are no more questions at this time, so I hand the conference back to the speakers for any closing comments.

Martin
23:45 - 24:33

Okay, so we have some questions here in the chat. So let us try to work through those. First one, our shipments to STADA are being resumed in Q4 2025. Yes. We made a shipment, although a limited one in Q3. So next week then is a good guess. Next question. Can you please clarify how much of the capitalized development cost as of Q3 relates specifically to the Xbrane project and what the remaining expected expenditure is to complete the ongoing collaboration with Intas? So, Jane, are you able to answer the first part of that?

Jane
24:33 - 24:45

Yeah, I think for the third quarter, about 65 million Swedish crowns were capitalized in relation to the Xbrane program.

Martin
24:47 - 25:43

Yeah. Regarding future expected expenditures for the program, as we've discussed before, we estimate it to amount to about 200 million Swedish crowns, net of commercial material coming out of that process. Our intention of financing that is via the inventory of Ximluci®, which is now gradually being converted into cash as we resume product deliveries to STADA. Next question. Can you elaborate on the main drivers behind the negative operating cash flow in Q3, given that reported costs were around 26 to 27 million Swedish crowns, but the total cash outflow exceeded 49? Is this something we will see in the coming quarters? Do you want to take this one, Jane?

Jane
25:44 - 26:35

I would say that the reported costs are not really 26 or 27 million; the bridge that I have tried to visualize of the outflow is not categorized in terms of costs and what is capitalized. However, I think that we will see less and less of negative cash outflow. And provided that we have now reached a status where the outflow of the operating expenses is more or less equal to the incoming revenue on a quarterly basis. And so, I don't think that we will see more of that in the coming quarters. That is my expectation.

Martin
26:38 - 32:15

Can you explain why the shipments were delayed in Q3? So, I think this was due to a delay in one of the manufacturing steps, resulting in one or two batches that we thought would be shipped in Q3 now being shipped in Q4. Next one, given the current burn rate and the additional 60 million Swedish Crown loan facility, how long is the company's operational runway under the current assumption? I mean, as per our current cash flow forecast, which then, of course, contains the expected product shipments to STADA and our forecasted expected profit sharing. From Ximluci® and so on. Uh, we, it tells us that we're going to be able to sustain throughout 2026 with the current cash position and in addition to this loan facility. 2026 with the current cash position and in addition to this loan facility. Yeah. Next question. What measures are being taken to stabilize cash flow going forward, for example, through improved payment terms with STADA and milestone payments from Intas or cost control initiatives? Yes, I would say all of those essentially, we are working on different angles, as we've done in the past with Intas and our suppliers to find different solutions to improve. Cash flow. And it's mainly, I would say, going forward. Important questions about the timing of different inflows and outflows, which we need to balance. And we are shifting out some consultants. But it's not that material in the whole context. I think we've done what we could there. It's more about balancing out development expenditures on different kinds of service providers, in particular in relation to the Xbrane program, with inflow expected from Ximluci®. Not only the profit sharing, but also the inventory buildup is being converted into cash. It's more about balancing out development expenditures on different kinds of service providers, in particular in relation to the Xbrane program with inflow expected from Ximluci®. Next question. What about the milestone from Intas? We received a milestone from Intas of about €2 million last quarter. And as per the agreement, there is a remaining €1 million milestone to come. Then it's contingent upon profit sharing to come post-launch of the product. Has the goal of achieving a 20% market share in Europe changed? Uh, no. That remains. I think we have all possibilities with Ximluci® and together with STADA to get towards a 20% volume market share. So that ambition remains. And why is the prefilled syringe taking so long? I think currently we're making some trade-offs, mainly from a cash flow perspective with regards to when we're starting and making certain investments. I think that's why we're now delaying the timeline a little bit on the prefilled syringe. Next question. Will you buy? OTC to increase shares. Will you buy OTC to increase shares? Are you getting that question, Jane? I'm not getting that question. Yeah, okay. Let's leave that one. We will leave that one. Anyway, those were the questions we received on the chat, and we are then going to conclude the call again. I fully understand that many of you out there are disappointed about this news coming from the FDA. We are equally disappointed over here. However, there's not much more to do than to get back at it and work together with the agency and the contract manufacturer in this case to resolve the issues and submit the application again. We hope that we are going to be able to provide some more clarity around those timelines in the coming weeks. So with that said, we thank you all for calling in and participating and wish you a good day.

Continue to the webcast
Pierce Group, Audiocast, Q3'26
Language: English11/13/2026, 8:00 AM
Göran Dahlin Good morning, everyone, and welcome to Pierce Group's presentation of our Q3 2026 interim results. Next slide, please. I am Göran Dahlin, CEO of Pierce Group, and I am with Fredrik Kjellg…
Surgical Science Sweden, Audiocast, Q3'26
Language: English11/12/2026, 10:00 AM
Tom Englund Hi everyone, and welcome to this earnings call for Surgical Science for the third quarter of 2026. My name is Tom Englund. I am the CEO. And with me today is our CFO, Anna Ahlberg. I wil…
ExpreS2ion Biotech – Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 9:00 AM
ExpreS2ion is expected to release its Q3 2026 interim report on 12 November 2026. Later the same day at 10.00, ExpreS2ion’s CEO Bent U. Frandsen and CFO Keith Alexander will present the results and answer questions in a live online event.
Meko Services AB, Q3'26
Language: English11/12/2026, 8:00 AM
Pat Thank you. Good morning, and welcome to MEKO's presentation of the third quarter of 2026. I am here with our CFO, Christy Johansson, and I will begin with an overview of the quarter and some of th…
WeSports Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Unknown 1 It. Ted Sporre Welcome to our Q3 release presentation. As you know, we have already shared preliminary figures for sales and EBITDA for this quarter, but today we complete the picture. We wi…
Nordrest Holding, Audiocast, Q3'26
Language: Swedish11/12/2026, 8:00 AM
Thomas Dahlstedt Hej och välkomna! Vi ska idag presentera Nordrests senaste kvartal och tillika resultatet för perioden. Jag som pratar nu heter Thomas Dahlstedt och är grundare och tillika VD för bol…
Karnov Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Pontus Bodelsson Welcome, everyone, to Karnov Group's earnings conference, where we will present the outcome of the third quarter of 2026. Please go to slide two. I am Pontus Bodelsson, President and…
Fasadgruppen Group, Audiocast, Q3'26
Language: English11/12/2026, 7:15 AM
Magnus Blomberg Perfect. Good morning and welcome to the Fasadgruppen presentation of our results for the third quarter 2026. My name is Magnus Blomberg. You have met me before. I am the CFO of Fasadg…
Munters AB, CMD
Language: English11/11/2026, 1:00 PM
Lena Dauvergne Good. Good afternoon everyone, and a warm welcome to Stockholm, to ESSEX and to Montage Capital Markets Day 2026. Montage Capital Markets Day 2026. It is really good to see so many of y…
Cinclus Pharma, Audiocast, Q3'26
Language: English11/11/2026, 1:00 PM
Christer Ahlberg Thank you. Hello and welcome to the Cinclus Pharma third quarter 2026 earnings call. I am Christer Ahlberg, CEO of Cinclus Pharma, and with me today is our CFO, Magnus Christensen. We…
Proact IT, CMD
Language: English11/11/2026, 12:30 PM
Unknown 1 The world of data is constantly changing. Breaches are rising, and attacks are getting more advanced. Regulation drives the need for data sovereignty. Data has to be available. Critical busi…
Ferronordic AB, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Henrik Good morning, everyone, and welcome to our presentation of the third quarter of 2026. During the quarter, we saw higher earnings, and growing aftermarket revenue was up 15% to 1.2 billion Swedi…
BICO, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Anders Fogelberg Good morning, everyone, and welcome to BICO's earnings call for the third quarter of 2026. I am Anders Fogelberg, President and CEO of BICO. And joining me today is our Group CFO, Ewa…
Catena Media, Audiocast, Q3'26
Language: English11/10/2026, 5:00 PM
Manuel Stan Good afternoon. Good evening, everyone. Welcome to the Catena Media Q3 Interim Report. I am Manuel Stan and today I'm joined by our Chief Financial Officer, Michael Gerrow. Today we will b…
Ellos Group, Q3'26
Language: English11/10/2026, 8:00 AM
Hans Ohlsson Live. Good morning, everyone, and welcome to the second presentation for Ellos Group as a listed company. We have 45 minutes today for the presentation. And there is a hard stop. After th…
Scandic Hotels Group, Audiocast, Q3'26
Language: English11/10/2026, 8:00 AM
Jens Mathisen Thank you so much, and good morning, everyone, and thank you for joining us for the Q3 presentation. I am Jens Mathisen, CEO of Scandic. And joining me is our CFO, Pierre Carstensen. We…
Svevik Industri, Q3'26
Language: Swedish11/6/2026, 9:00 AM
Johan Hårdén Tack så mycket! Hello and welcome to this hearing regarding the Q3 2026 interim report. We have an agenda where we intend to introduce ourselves to all the new shareholders as well. Kort…
Attendo, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Martin Tivéus Good morning, everyone, and thank you for joining us. Today, we will present our results for the third quarter of 2026. I am pleased to announce that this is the strongest quarter for At…
Cavotec, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
David Pagels Good morning and welcome to Cavotec's Q3 2026 presentation. I am David Pagels, the CEO of Cavotec. And together with me today, I have our new CFO, Christoffer Robertsson. I would like to…
Fractal Gaming Group, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Jonas Good morning, everyone, and welcome to Fractal's Q3 2026 presentation. Today, we'll take you through our results, the progress that we've made, and our priorities ahead after a difficult first h…